The largest international gathering of breast cancer researchers returns to San Antonio and continues to lead as the hub for scientific breakthroughs. Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 48^th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 9-12.

The ESMO Immuno-Oncology Congress 2025 will take place from 10–12 December in London, UK, bringing together specialists in cancer immunotherapy to present and discuss research in this promising field, spanning all areas from basic and translational science to the latest clinical developments

A new study examined CRAFT-G, a remote group intervention combining cognitive training, psychoeducation, and occupational-therapy–based strategies for adults experiencing cancer-related cognitive impairment. The small pilot found high satisfaction, strong retention, and clinically meaningful improvements in daily functioning and self-perceived cognitive abilities among cancer survivors. The findings suggest that remote, group-based cognitive rehabilitation may offer an accessible and effective path to helping survivors manage “chemobrain” and reclaim everyday life.

A study from the Hospital del Mar Research Institute, published in The Journal of Clinical Investigation, indicates that the high expression of the estrogen receptor is the main factor preventing the most common type of breast cancer, luminal breast cancer, from responding to immunotherapy.

The high presence of the estrogen receptor sequesters the LCOR molecule, whose action on tumor cells is necessary to make tumors visible to the immune system. In experimental models, the researchers found that combining immunotherapy with endocrine therapy allows LCOR to function and the immune system to attack the tumor.

At the same time, they have generated a modified version of the LCOR molecule that sensitizes tumors to immunotherapy, including those with hormone receptors. The next goal is to study this molecule combined with immunotherapy in clinical trials.

A team at CABIMER has developed PLAMseq, a technique that for the first time enables the simultaneous identification of chromatin-associated proteins and their precise genomic locations within a single experiment, overcoming limitations of traditional methods like ChIP-seq and mass spectrometry that require complex workflows and specific antibodies. By leveraging rapid TurboID-mediated biotinylation, PLAMseq uncovers previously unknown molecular interactions—such as SETDB1 binding to SUMO-modified histones—and demonstrates strong performance on key genome regulators including CTCF, RNA polymerase II, and modified H1 histones. This integrated proteogenomic approach opens new avenues for investigating epigenetic mechanisms underlying cancer and neurological or developmental disorders, potentially accelerating the discovery of therapeutic targets and biomarkers while positioning Andalusian research groups at the forefront of chromatin biology innovation.